natgillin/translations-raw huggingface dataset:
A total of 67 patients have been treated and 50 (74%) patients remain on treatment, made up of 38 (76%) patients in the treatment-naïve group, 9 (18%) in the APPROACH-volanesorsen group and 3 (6%) in the CS16-volanesorsen group. 
Liječeno je ukupno 67 bolesnika, a njih 50 (74%) nastavilo je primati terapiju što čini 38 (76%) bolesnika u skupini koja nije prethodno liječena, 9
Insomnia (1, 1%) 
Nesanica (1, 1%)
Haematuria (1, 1%) Proteinuria (1, 1%) 
Hematurija (1, 1%) Proteinurija (1, 1%)
• Leak-resistant, 
• otporan na propuštanje,
Injection site mass (2, 2%) Pain (2, 2%) 
Upala na mjestu injekcije (2, 2%) Masa na mjestu injekcije (2, 2%) Bol (2, 2%)
In vitro studies show that volanesorsen is not a substrate or inhibitor of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptides (OATP1B1, OATP1B3), bile salt export pump (BSEP), organic cation transporters (OCT1, OCT2), or organic anion transporters (OAT1, OAT3). 
In vitro ispitivanja pokazuju da volanesorsen nije supstrat ili inhibitor P-glikoproteina (P-gp), proteina otpornosti raka dojke na lijekove (BCRP), transportnih polipeptida za organske anione
Figure O 
slika O
What you need to know before you use Waylivra Do not use Waylivra if: 
Nemojte primjenjivati Waylivru ako:
Figure D 
slika D
Figure L 
slika L
Wash hands and gather supplies 
Operite ruke i pripremite sve što Vam je potrebno za injekciju
Diabetes mellitus (1, 1%) 
Dijabetes melitus (1, 1%)
Erythema (4, 5%) Pruritus (4,5 %) Urticaria (3, 3%) Hyperhidrosis (2, 2%) Rash (3, 3%) Petechiae (1, 1%) Ecchymosis (1, 1%) Night sweats (1, 1%) Papule (1, 1%) Skin hypertrophy (1, 1%) Swelling face (1, 1%) 
Eritem (4, 5%) Pruritus (4, 5%) Urtikarija (3, 3%) Hiperhidroza (2, 2%) Osip (3, 3%) Petehije (1, 1%) Ekhimoza (1, 1%)
Do not rub the site after you've injected. 
Nemojte trljati mjesto davanja injekcije nakon injekcije.
This medicinal product has not been studied in patients with hepatic impairment. 
Ovaj lijek nije ispitivan u bolesnika s oštećenjem funkcije jetre.
Figure M 
slika M
o Information about the FCS disease registry and the PASS study and the importance of contributing to those studies. 
Bolesnike se mora podsjećati da pročitaju uputu o lijeku te vodič za bolesnika/njegovatelja o Informacije o registru za FCS te PASS ispitivanje kao i važnost doprinosa tim ispitivanjima
Weekly 
Tjedno
Eye disorders 
Poremećaj oka
Figure P 
slika P
Remove needle cap 
Skinite kapicu igle
You should see your doctor immediately if you have any signs of kidney damage, such as swelling in your ankles, legs and feet, passing smaller amounts of urine than usual, shortness of breath, feeling sick, confusion or feeling very tired or drowsy. 
Morate se odmah javiti liječniku ako imate bilo kakve znakove oštećenja bubrega poput oticanja u gležnjevima, nogama ili stopalima, smanjeno izmokravanje u odnosu na inače, nedostatak zraka, mučninu, zbunjenost ili osjećaj velikog umora ili omamljenost.
Waylivra should be injected under your skin in the way the doctor, nurse or pharmacist has shown you, and you should make sure you inject all of the liquid in the syringe. 
Waylivra se mora injicirati pod kožu (supkutano) na način koji Vam je pokazao liječnik,
Waylivra 285 mg solution for injection in pre-filled syringe 
Waylivra 285 mg otopina za injekciju u napunjenoj štrcaljki
Waylivra 285 mg solution for injection in pre-filled syringe volanesorsen 
Waylivra 285 mg otopina za injekciju u napunjenoj štrcaljki volanesorsen
P-values from logistic regression model with treatment, presence of pancreatitis and presence of concurrent omega-3 fatty acids and/or fibrates as factors, and logarithm-transformed baseline fasting triglycerides as a covariate. 
P-vrijednosti iz modela logističke regresije s liječenjem, prisutnošću pankreatitisa i istodobne terapije omega-3
They may change how often you use it, or may stop it for a period or permanently, depending on the results of your blood and urine tests or occurrence of side effects. 
Liječnik Vam može promijeniti učestalost primjene ovog lijeka ili može privremeno ili trajno prekinuti liječenje njime, ovisno o
Epistaxis (3, 3%) Cough (1, 1%) Dyspnoea (2, 2%) Nasal congestion (1, 1%) Pharyngeal oedema (1, 1%) Wheezing (1, 1%) 
Epistaksa (3, 3%) Kašalj (1, 1%) Dispneja (2, 2%) Nazalna kongestija (1, 1%) Faringealni edem (1, 1%) Piskanje (1, 1%)
Treat the Injection Site 
Pobrinite se za mjesto davanja injekcije
LDL-C 
Razine LDL-C
Table 1. 
Slika 1:
APPROACH-volanesorsen (Index Study Baselinea, N=14) 
(početak indeksirajućeg ispitivanjaa, N=14)
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 
U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se liječniku ili ljekarniku ili medicinskoj sestri.
Choose an injection site If self-injecting: 
Ako si sami dajete injekciju:
Haematoma (3, 3%) Hypertension (1, 1%) Haemorrhage (1, 1%) Hot flush (1, 1%) 
Hematom (3, 3%) Hipertenzija (1, 1%) Krvarenje (1, 1%) Navala crvenila (1, 1%)
Figure J 
slika J
Figure G 
slika G
Treatment-naïve Group (Open-label Study Baselinea, N=51) 
(početak otvorenog ispitivanjaa, N=51)
Pyrexia (4, 5%) 
Zimica (5, 6%) Pireksija (4, 5%)
Dispose of the Used Syringe into a Sharps Container 
Nakon davanja injekcije 12. Bacite iskorištenu štrcaljku u spremnik za oštre predmete
If you get any of the following side effects, contact your doctor immediately: - Symptoms that could indicate low counts of platelets in your blood (platelets are cells important for blood clotting). 
- simptomi koji mogu ukazivati na nizak broj trombocita u Vašoj krvi (trombociti su stanice bitne za zgrušavanje krvi).
a Baseline values for treatment-naïve group were taken from the open-label study CS7 and baseline for 
Početne vrijednosti za skupinu koja nije prethodno liječena uzete su iz otvorenog ispitivanja CS7, a za skupine liječene volanesorsenom u sklopu ispitivanja APPROACH i CS16 uzete su iz odgovarajućeg indeksirajućeg ispitivanja.
Injection site hypoaesthesia (4, 
Krvarenje na mjestu injekcije (4, Hipoestezija na mjestu injekcije
Blood urea increased (1, 1%) Creatinine renal clearance decreased (1, 1%) Transaminases increased (1, 1%) White blood cell count decreased 
Povišen kreatinin u krvi (1, 1%) Povišena urea u krvi (1, 1%) Smanjen bubrežni klirens kreatinina (1, 1%) Povišene transaminaze (1, 1%) Smanjen broj leukocita (1, 1%) Smanjen hemoglobin (1, 1%)
Percent Change from Baseline in Fasting Triglycerides: Subset of Patients with Non-Missing Endpoints, Full Analysis Set 
Podskupina bolesnika bez nedostajućih mjera ishoda, potpuni skup podataka za analizu
o That patients should be made aware of the possibility of thrombocytopaenia and to seek medical attention immediately in case of signs of bleeding. 
o Preporuke za praćenje razine trombocita koje uključuju preporuke za prilagodbu doziranja, i prije i tijekom liječenja o Potrebno je osigurati da su bolesnicima svjesni mogućnosti trombocitopenije te da je potrebno odmah potražiti liječničku pomoć u slučaju znakova krvarenja.
% change from Baseline in CS16 
Liječeni volanesorsenom u ispitivanju CS16
Figure K 
slika K
Figure 1: LS Mean Percent Change in Fasting Triglycerides in Phase 3 Study in Patients with FCS (APPROACH) 
LS srednja vrijednost postotka promjene razine triglicerida natašte u bolesnika s FCS-om (APPROACH) u ispitivanju faze 3
Almac Pharma Services Ireland Ltd. Finnabair Industrial Estate Dundalk 
Almac Pharma Services Ireland Ltd.
Solution for injection in pre-filled syringe 1 pre-filled syringe. 
Otopina za injekciju u napunjenoj štrcaljki.
Prepare injection site 
Injiciranje 6. Pripremite mjesto injiciranja
Gastrointestinal disorders 
Hilomikronski trigliceridi
Nausea (8, 9%) Diarrhoea (4, 5%) Dry mouth (1,1 %) 
Proljev (4, 5%) Suha usta (1, 1%) Krvarenje desni (1, 1%)
LS Mean % Change from Baseline 
LS srednja vrijednost % promjene u odnosu na početnu vrijednost
Leukopenia (2, 2%) Eosinophilia (1, 1%) Immune thrombocytopenic purpura (1, 1%) 
Leukopenija (2, 2%) Eozinofilija (1, 1%)
Injection site haematoma (7, 8%) Injection site reaction (6, 7%) Injection site urticaria (5, 6%) Injection site warmth (5, 6%) Chills (5, 6%) 
Hematom na mjestu injekcije (7, Reakcija na mjestu injekcije (6, Urtikarija na mjestu injekcije (5,
0 NC 
0 NI
Clinically relevant pharmacokinetic interactions are not expected between volanesorsen and substrates, inducers or inhibitors of cytochrome P450 (CYP) enzymes, and drug transporters. 
induktora ili inhibitora citokroma P450 (CYP) te transportera lijeka.
Diet 
Prehrana
Posology 
slika
Breastfeeding 
Trigliceridi
Patients with lower body weight (less than 70 kg) may be more prone to thrombocytopenia during treatment with this medicinal product. 
mogu biti skloniji trombocitopeniji tijekom liječenja ovim lijekom.
LDL-C Levels 
Ukupni kolesterol LDL-C
Patients should be re-downtitrated to 285 mg every 2 weeks if the higher 285 mg once weekly dose does not provide significant additional triglyceride reduction after 9 months. 
Bolesnicima treba ponovno smanjiti doziranje lijeka na 285 mg svaka 2 tjedna ako doziranje od 285
In the placebo group, of the 4 patients who had 17 adjudicated pancreatitis attacks in the prior 5 years, 3 patients experienced 4 pancreatitis attacks during the 52-week treatment period. 
događaja procijenjenih kao napadaj pankreatitisa u prethodnih 5 godina, 3 bolesnika iskusila su 4
The medicine should be clear to slightly yellow in color. 
Tekućina mora biti bistra te bezbojna do žućkasta.
Do not attempt to remove the air bubble. 
Nemojte ga pokušavati istisnuti.
How to store Waylivra 6. 
Moguće nuspojave 5. Kako čuvati Waylivru
• The patient information pack should contain: o Patient information leaflet o A patient/carer guide 
• Paket s informacijama za bolesnika treba sadržavati:
Do not inject into tattoos, moles, scars, birthmarks, bruises, rashes, or areas where the skin is tender, red, hard, damaged, burned, or inflamed. 
Nemojte injicirati lijek u tetovaže, madeže, urođene promjene na koži, modrice, osipe ili područja gdje je slika F
Figure A 
slika E
Description of selected adverse reactions 
Opis odabranih nuspojava Trombocitopenija
Table 3: Mean Baseline and Percent Change in Lipid Parameters from Baseline to Month 3 
Tablica 3: Srednje vrijednosti lipidnih parametara na početku liječenja i postotak promjene u 3. mjesecu u odnosu na početne vrijednosti
CS16-volanesorsen (Index Study Baselinea, N=3) 
(početak indeksirajućeg ispitivanjaa, N=3)
Spontaneous haematoma (1, 1%) 
Imuna trombocitopenična purpura (1, 1%) Spontani hematom (1, 1%)
Monitoring Frequency 
Mehanizam djelovanja
Injecting 6. 
Suhoća na mjestu injekcije (4,
If you get any side effects, talk to your doctor, pharmacist or nurse. 
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika, ili ljekarnika ili medicinsku sestru.
Insert needle 
Prijavljivanje nuspojava
Injection site paraesthesia (1, 1%) Injection site scab (1, 1%) Injection site papule (1, 1%) Oedema (1, 1%) 
Papule (1, 1%) Hipertrofija kože (1, 1%) Oticanje lica (1, 1%)
After first opening of the container: 6 months. 
Nakon prvog otvaranja spremnika: 6 mjeseci.
[For outer carton only] PC: 
(Samo za vanjsko pakiranje) PC:
If you are an elderly patient (over 65 years of age), you should take Pregabalin Sandoz normally except if you have problems with your kidneys. 
Ako ste bolesnik u starijoj dobi (iznad 65 godina), lijek Pregabalin Sandoz trebate uzimati normalno, osim ako imate problema s bubrezima.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines webportal. 
Zahtjevi za podnošenjem ažuriranih periodičkih izvješća o neškodljivosti za ovaj lijek navedeni su u referentnom popisu datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i naknadne izmjene objavljene na europskom internetskom portalu za lijekove.
Warnings and Precautions Talk to your doctor or pharmacist before taking Pregabalin Sandoz. 
Upozorenja i mjere opreza Obratite se svom liječniku ili ljekarniku prije nego uzmete Pregabalin Sandoz.
* Alanine aminotransferase increased (ALT) and aspartate aminotransferase increased (AST). 
*povećanje alanin aminotransferaze (ALT) i aspartat aminotransferaze (AST).
HDPE bottles: Use within 6 months after first opening. 
HDPE boce: Uporabiti unutar 6 mjeseci od prvog otvaranja.
Do not take Pregabalin Sandoz: If you are allergic to pregabalin or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati Pregabalin Sandoz: Ako ste alergični na pregabalin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
Following a dose of radiolabelled pregabalin, approximately 98% of the radioactivity recovered in the urine was unchanged pregabalin. 
Nakon primjene doze radioaktivno označenog pregabalina oko 98 % radioaktivnosti ustanovljene u mokraći bio je nepromijenjen pregabalin.
Pregabalin Sandoz and certain other medicines may influence each other (interaction). 
Pregabalin Sandoz i neki drugi lijekovi mogu djelovati jedni na druge (interakcija).
Seizures were also reported. 
Napadaji su također prijavljeni.
A meta- analysis of randomised placebo controlled studies of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. 
Meta-analiza randomiziranih placebom kontroliranih ispitivanja antiepileptika ukazala je i na malo povećan rizik od suicidalnih ideja i ponašanja.
Pregabalin Sandoz should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus). 
Pregabalin Sandoz se ne smije primjenjivati tijekom trudnoće osim ako to nije neophodno (ako korist liječenja za majku jasno nadilazi mogući rizik za plod).
The adverse reactions listed may also be associated with the underlying disease and / or concomitant medicinal products. 
Navedene nuspojave mogu biti povezane i s osnovnom bolešću i/ili istodobno primijenjenim lijekovima.
Withdrawal of concomitant antiepileptic medicinal products 
Ukidanje istodobno primjenjivanih antiepileptika
Inter-subject pharmacokinetic variability for pregabalin is low (< 20%). 
Razlike u farmakokinetici pregabalina od osobe do osobe su male (< 20 %).
If you take more Pregabalin Sandoz than you should Call your doctor or go to the nearest hospital emergency unit immediately. 
Ako uzmete više lijeka Pregabalin Sandoz nego što ste trebali Odmah nazovite svog liječnika ili otiđite u hitnu službu najbliže bolnice.
Take your box or bottle of Pregabalin Sandoz capsules with you. 
Uzmite sa sobom kutiju ili bočicu Pregabalin Sandoz kapsula.
It is advised not to drink alcohol while taking Pregabalin Sandoz. 
Preporučuje se da ne pijete alkohol dok uzimate lijek Pregabalin Sandoz.
• A small number of people being treated with anti-epileptics such as Pregabalin Sandoz have had thoughts of harming or killing themselves. 
• Mali broj ljudi koji se liječe antiepileptičkim lijekovima kao što je Pregabalin Sandoz razmišljali su o samoozljeđivanju ili samoubojstvu.
These symptoms may occur more commonly or severely if you have been taking Pregabalin Sandoz for a longer period of time. 
Ti simptomi mogu biti češći ili ozbiljniji ako ste lijek Pregabalin Sandoz uzimali dulje vrijeme.
The rate of pregabalin absorption is decreased when given with food resulting in a decrease in Cmax by approximately 25-30% and a delay in tmax to approximately 2.5 hours. 
Brzina apsorpcije pregabalina smanjuje se kada se lijek primjenjuje s hranom, što dovodi do smanjenja Cmax za približno 25-30 %, dok je tmax odgođen na približno 2,5 sata.
If you have the impression that the effect of Pregabalin Sandoz is too strong or too weak, talk to your doctor or pharmacist. 
Ako Vam se čini da je djelovanje lijeka Pregabalin Sandoz prejako ili preslabo, porazgovarajte sa svojim liječnikom ili ljekarnikom.
The degree of dizziness, sleepiness and decreased concentration may be increased if Pregabalin Sandoz is taken together with medicines containing: 
Omaglica, pospanost i smanjenje koncentracije mogu se pojačati ako se Pregabalin Sandoz uzima zajedno s lijekovima koji sadrže:
Your doctor will tell you to take Pregabalin Sandoz either twice or three times a day. 
Liječnik će Vam reći da uzmete lijek Pregabalin Sandoz dva puta ili tri puta na dan.
Women of childbearing potential / Contraception in males and females As the potential risk for humans is unknown, effective contraception must be used in women of child bearing potential. 
Žene reproduktivne dobi / kontracepcija u muškaraca i žena Budući da potencijalan rizik za ljude nije poznat, žene reproduktivne dobi moraju koristiti učinkovitu kontracepciju.
Do not use this medicine after the expiry date which is stated on the blister, container or carton. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na blisteru, spremniku ili kutiji.
• Pregabalin Sandoz may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary. 
• Pregabalin Sandoz može uzrokovati zamagljen vid, gubitak vida ili druge promjene vida, od kojih su mnoge privremene.
Starting dose (mg/day) Maximum dose (mg/day) 
Početna doza (mg/dan) Maksimalna doza (mg/dan)
Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar. 
Profili sigurnosti i djelotvornosti za BID i TID režim doziranja općenito su bili podjednaki.
Pregabalin Sandoz with food, drink and alcohol Pregabalin Sandoz capsules may be taken with or without food. 
Pregabalin Sandoz s hranom, pićem i alkoholom Pregabalin Sandoz kapsule mogu se uzimati s hranom ili bez nje.
Бул.“Никола Вапцаров“ No. 55 сгр. 
Бул.“Никола Вапцаров“
Pregabalin binds to an auxiliary subunit (α2-δ protein) of voltage-gated calcium channels in the central nervous system, 
Pregabalin se veže na pomoćnu podjedinicu (α2-δ protein) na električni napon osjetljivih kalcijevih kanala u središnjem živčanom sustavu.
A decision must be made whether to discontinue breast-feeding or to discontinue pregabalin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Potrebno je odlučiti da li prekinuti dojenje ili prekinuti liječenje pegabalinom uzimajući u obzir korist dojenja za dijete i korist liječenja za ženu.
Pregabalin Sandoz is not intended to be used alone, but should always be used in combination with other anti-epileptic treatment. 
Pregabalin Sandoz nije namijenjen za samostalnu primjenu, nego se uvijek mora uzimati u kombinaciji s drugim antiepileptičkim lijekovima.
Continue taking Pregabalin Sandoz until your doctor tells you to stop. 
Nastavite uzimati lijek Pregabalin Sandoz dok Vam liječnik ne kaže da prestanete.
Ophthamologic testing (including visual acuity testing, formal visual field testing and dilated funduscopic examination) was conducted in over 3600 patients within controlled clinical trials. 
Oftalmološke pretrage (uključujući mjerenje oštrine vida, formalno ispitivanje vidnog polja i fundoskopski pregled nakon širenja zjenica) su u sklopu kontroliranih kliničkih ispitivanja provedene u više od 3600 bolesnika.
Pregabalin Sandoz should not be taken during pregnancy or when breast-feeding, unless you are told otherwise by your doctor. 
Pregabalin Sandoz se ne smije uzimati tijekom trudnoće ili dojenja, osim ako Vam liječnik nije rekao drugačije.
PVC/PVDC//Alu blister. 
PVC/PVDC//aluminij blister.
OUTER CARTON FOR CONTAINER AND LABEL FOR CONTAINER 
VANJSKO PAKIRANJE ZA SPREMNIK I NALJEPNICA ZA SPREMNIK
UNIQUE IDENTIFIER - HUMAN READABLE DATA [For outer carton only] 
JEDINSTVENI IDENTIFIKATOR - PODACI ČITLJIVI LJUDSKIM OKOM (Samo za vanjsko pakiranje)
Pregabalin oral bioavailability is estimated to be ≥90% and is independent of dose. 
Procjenjuje se da bioraspoloživost peroralno primijenjenog pregabalina iznosi ≥ 90 % i ne ovisi o dozi.
• When Pregabalin Sandoz is taken with other medicines that may cause constipation (such as some types of pain medicines) it is possible that gastrointestinal problems may occur (e.g. constipation, blocked or paralysed bowel). 
• Kada se Pregabalin Sandoz uzima s drugim lijekovima koji mogu uzrokovati zatvor (kao što su neke vrste lijekova protiv bolova), moguće je da se pojave probavne tegobe (primjerice zatvor, blokada ili paraliza crijeva).
Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). 
Pregabalin se iz plazme djelotvorno uklanja hemodijalizom (50 % lijeka tijekom 4 sata).
The safety and efficacy of pregabalin in children below the age of 12 years and in adolescents (12-17 years of age) have not been established. 
Sigurnost i djelotvornost pregabalina u djece mlađe od 12 godina i adolescenata (12-17 godina) nisu ustanovljene.
What Pregabalin Sandoz is and what it is used for 
Što je Pregabalin Sandoz i za što se koristi
The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose. 
N-metilirani derivat pregabalina, glavni metabolit pregabalina ustanovljen u mokraći, činio je 0,9 % doze.
Pregabalin Sandoz may be taken with or without food. 
Pregabalin Sandoz se može uzimati s hranom ili bez nje.
• Heart rhythm disturbances, increased heart rate, low blood pressure, high blood pressure, changes in heart beat, heart failure. 
• poremećaji srčanog ritma, ubrzano kucanje srca, nizak krvni tlak, visok krvni tlak, promjene srčanog ritma, zatajenje srca
Pregabalin Sandoz may be taken with oral contraceptives. 
Pregabalin Sandoz se može uzimati s oralnim kontraceptivima.
What Pregabalin Sandoz contains - The active substance is pregabalin. 
Što Pregabalin Sandoz sadrži - Djelatna tvar je pregabalin.
Pregabalin Sandoz may produce dizziness, sleepiness and decreased concentration. 
Pregabalin Sandoz može izazvati omaglicu, pospanost i smanjenu koncentraciju.
If while taking Pregabalin Sandoz you notice decreased urination, you should tell your doctor as stopping the medicine may improve this. 
Ako tijekom uzimanja lijeka Pregabalin Sandoz primijetite da manje mokrite, morate o tome obavijestiti svog liječnika jer se prekidom primjene lijeka to može poboljšati.
In addition, pregabalin is effectively removed from plasma by haemodialysis (following a 4 hour haemodialysis treatment plasma pregabalin concentrations are reduced by approximately 50%). 
Nadalje, pregabalin se iz plazme djelotvorno uklanja hemodijalizom (nakon četverosatne hemodijalize koncentracije pregabalina u plazmi smanjuju se za približno 50 %).
- The other ingredients are pregelatinised maize starch, maize starch, talc, gelatin, titanium dioxide (E171), yellow iron oxide (E172) (all strengths except 150 mg), red iron oxide (E172) (all strengths except 50 mg and 150 mg), black iron oxide (E172) (only 25 mg and 300 mg). 
- Drugi sastojci su: preželatinizirani kukuruzni škrob, kukuruzni škrob, talk, želatina, titanijev dioksid (E171), žuti željezov oksid (E172) (sve jačine osim 150 mg), crveni željezov oksid (E172) (sve jačine osim 50 mg i 150 mg), crni željezov oksid (E172) (samo 25 mg i 300 mg).
C/Serrano Galvache, N°56 28033 Madrid 
C/Serrano Galvache, N°56
Sandoz Farmacéutica, S.A. Centro empresarial Parque Norte Edificio Roble 
Centro empresarial Parque Norte Edificio Roble
Peripheral and central neuropathic pain: Pregabalin Sandoz is used to treat long lasting pain caused by damage to the nerves. 
Periferna i centralna neuropatska bol: Pregabalin Sandoz se koristi za liječenje dugotrajne boli uzrokovane oštećenjem živaca.
EXP Use within 6 months after first opening. 
Uporabiti unutar 6 mjeseci od prvog otvaranja.
Epilepsy: Pregabalin Sandoz is used to treat a certain form of epilepsy (partial seizures with or without secondary generalisation) in adults. 
Epilepsija: Pregabalin Sandoz se koristi za liječenje nekih oblika epilepsije (parcijalnih napadaja sa ili bez sekundarne generalizacije) u odraslih osoba.
Your doctor will prescribe Pregabalin Sandoz for you to help treat your epilepsy when your current treatment is not controlling your condition. 
Liječnik će Vam propisati lijek Pregabalin Sandoz za liječenje epilepsije kada lijekovi koje ste do sada uzimali bolest ne drže pod kontrolom.